08/02/2012 Pradaxa Lawyer: Pradaxa Lawyer groups are being sought out after the U.S. Food and Drug Administration released information regarding Pradaxa and excessive bleeding events. To speak with Pradaxa Lawyers regarding your legal rights and options, please call our helpline or our evaluation form and Best Legal Source will contact you as soon as possible.
What legal action is available to those seeking Pradaxa Lawyer assistance?
If you or someone in your family has been harmed by Pradaxa, it might be important to consult with your Pradaxa Lawyer so you are aware of the complete scope of information available to you. A Pradaxa Class Action would bring together many individuals who essentially have the same injury. Pradaxa Lawsuit Multidistrict Litigation (MDL) represents many people with individual cases. In either case, a Pradaxa Lawyer can help you with legal decisions if you have had any severe complications after taking Pradaxa. Do not pass up your opportunity to take action. The law limits the amount of time you have to file Pradaxa Lawsuit cases, so do not wait any longer to contact us. Take the first step in getting the justice you deserve by letting a Pradaxa Lawyer help you!
Can you file a Pradaxa Lawsuit without paying the Pradaxa Lawyer up front?
The call and consultation to discuss filing Pradaxa Lawsuit cases are free. Best Legal Source only connects you with contingency fee attorneys. These Pradaxa Lawyer groups agree to represent you and will only get paid if you win. They then take their fee from a percentage of what you are awarded. Contingency attorneys like the Pradaxa Lawyer do take risks in these cases, and many clients would not be able to afford attorneys if all attorneys wanted to be paid hourly. Call Best Legal Source if you would like to speak with a Pradaxa Lawyer.
Details leading to Pradaxa Lawyer interest
Pradaxa Lawsuit information involves concerns over Pradaxa, an anti-coagulant medication, approved by the U.S. Food and Drug Administration in October 2010. Pradaxa is used to prevent strokes in individuals with irregular heartbeats called atrial fibrillation. If you experience any of the following serious symptoms, call your doctor immediately or get emergency medical treatment: bleeding from the gums; frequent nosebleeds, unusual bruising or bleeding; heavy menstrual bleeding; pink or brown urine; coughing up blood; red or black tarry stools; a cut that bleeds longer than normal; vomit that is blood or looks like coffee grounds; and headache. If you would like a free consultation with a Pradaxa Lawsuit attorney, call Best Legal Source today.
Pradaxa Lawyer Contact Procedures from Best Legal Source
To close, we would like to give you contact information for Pradaxa Lawyer groups who are looking into Pradaxa Class Action and Pradaxa Lawsuit cases. Please call (800) 611-7080 to reach Best Legal Source directly. We will then connect you with a free consultation with a Pradaxa Lawyer who can help you determine whether a Pradaxa Class Action or individual Pradaxa Lawsuit is best for your situation. Take the best step for your future by acting today.
Additional Pradaxa Lawyer Reading Material
To further your understanding of the Pradaxa Lawsuit process, we have included information from an actual Pradaxa Lawsuit filed by a Pradaxa Lawyer in the East St. Louis Division of Illinois for Eva Smith. The comments within the Pradaxa Lawsuit written by Best Legal Source are delineated by headers. These portions should not be taken as legal opinion or advice.
Eva Smith Pradaxa Lawsuit Content
2012 WL 1834764 (S.D.Ill.) (Trial Pleading)
United States District Court, S.D. Illinois,
East St. Louis Division.
Eva SMITH, Plaintiff,
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., Boehringer Ingelheim Corporation, Boehringer Ingelheim USA Corporation, and Boehringer Ingelheim Vetmedica, Inc., Defendants.
May 11, 2012.
Jury Trial Demanded
Specific Pradaxa Lawyer and Plaintiff Information Explained
We have omitted some content such as the Pradaxa Lawyers information from this introductory statement. The Pradaxa Lawsuit plaintiff and defendant information is listed below as well as the factual statements within the Pradaxa Lawsuit.
Pradaxa Lawsuit of Eva Smith in Illinois
At all times relevant hereto, Plaintiff was a resident and citizen of Godfrey, Illinois located in Madison County.
Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer”) is a Delaware corporation which has its principal place of business at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Boehringer can be served via its registered agent: CT Corporation System, 208 South LaSalle, Suite 814, Chicago, IL 60604. Boehringer has conducted business and derived substantial revenue from within the State of Illinois.
Pradaxa® is a direct thrombin inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Patients with atrial fibrillation have an increased risk of stroke. Pradaxa® was approved by the Food and Drug Administration (“FDA”) on October 19, 2010. The FDA approved two dosages: 75 mg and 150 mg, to be taken twice daily.
Defendants promoted Pradaxa® as a novel medicine for patients with non-valvular atrial fibrillation. Defendants’ marketing campaign for Pradaxa® included promoting it as being more effective than warfarin in preventing stroke and systemic embolism, providing a convenient alternative to warfarin therapy because it does not require blood monitoring or dose adjustments, and does not require any dietary restrictions.
In the course of these direct to consumer advertisements, Defendants overstated the efficacy of Pradaxa® with respect to preventing stroke and systemic embolism, failed to adequately disclose to patients that there is no drug, agent or means to reverse the anticoagulation effects of Pradaxa®, and that such irreversibility could have permanently disabling, life-threatening and fatal consequences.
Marketing affects decision to enter Pradaxa Lawsuit
The Pradaxa Lawsuit defendants marketed and over-promoted Pradaxa according to the Pradaxa Lawsuit document. The following section demonstrates the practices of the Pradaxa Lawsuit defendant which led to harm for the plaintiff and Pradaxa Lawyer involvement. You can read the following information and call us if you are looking for Pradaxa Lawyer guidance.
Sales, Marketing and Warnings by Pradaxa Lawsuit Defendants
Prior to Plaintiff’s prescription of Pradaxa®, Plaintiff’s prescribing physician received promotional materials and information from sales representatives of Defendants that Pradaxa® was more effective than warfarin in reducing strokes in patients with non-valvular atrial fibrillation and was more convenient, without also adequately informing prescribing physicians that there was no reversal agent that could stop or control bleeding in patients taking Pradaxa®.
At all times relevant hereto, Defendants also failed to warn emergency room doctors, surgeons and other critical care medical professionals that unlike generally-known measures taken to treat and stabilize bleeding in users of warfarin, there is no effective agent to reverse the anticoagulation effects of Pradaxa®, and therefore no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Pradaxa®.
At all times relevant to this action, The Pradaxa® Medication Guide, prepared and distributed by Defendants and intended for U.S. patients to whom Pradaxa® has been prescribed, failed to warn and disclose to patients that there is no agent to reverse the anticoagulation effects of Pradaxa® and that if serious bleeding occurs, it may be irreversible, permanently disabling, and life-threatening.
U.S. Food and Drug Administration and Pradaxa Lawsuit Action
Typically a warning from the FDA will precede any lawsuit action such as the Pradaxa Lawsuit. Within the Pradaxa Lawsuit document, the released safety communications from the FDA are listed below. Pradaxa Lawyer groups include this information because it adds legitimacy to the case.
FDA Release Increase Pradaxa Lawsuit Interest
From October 2010 until the end of March 2011, approximately 272,119 prescriptions for Pradaxa® were written in the United States. During that same period, there were 932 Pradaxa®-associated “Serious Adverse Event” (“SAE”) Medwatch reports filed with the U.S. Food and Drug Administration, including at least 120 deaths and over 500 reports of severe, life-threatening bleeding.
From April 1 until the end of June 2011, there were an additional 856 Pradaxa®-associated “SAE” Medwatch reports filed with the U.S. Food and Drug Administration including at least 117 deaths and over 510 reports of severe, life-threatening bleeding.
During the Defendants’ 2011 fiscal year, worldwide Pradaxa® sales eclipsed the $1 billion threshold, achieving what is commonly known in the pharmaceutical industry as “blockbuster” sales status.3
Defendants original labeling and prescribing information for Pradaxa®:
a. failed to disclose in the “Warnings” Section that there is no drug, agent or means to reverse the anticoagulation effects of Pradaxa®;
b. failed to advise prescribing physicians, such as the Plaintiff’s physician, to instruct patients that there was no agent to reverse the anticoagulant effects of Pradaxa®;
c. failed to investigate, research, study and consider, fully and adequately, patient weight as a variable factor in establishing recommended dosages of Pradaxa®;
d. failed to investigate, research, study and define, fully and adequately, the safety profile of Pradaxa®;
e. failed to provide adequate warnings about the true safety risks associated with the use of Pradaxa®;
f. failed to warn that it is difficult or impossible to assess the degree and/or extent of anticoagulation in patients taking Pradaxa®;
g. failed to provide adequate instructions on how to intervene and/or stabilize a patient who suffers a bleed while taking Pradaxa®;
h. failed to provide adequate warnings regarding the need to assess renal functioning prior to starting a patient on Pradaxa® and to continue testing and monitoring of renal functioning periodically while the patient is on Pradaxa®;
i. failed to provide adequate warnings and information related to the increased risks of bleeding events associated with aging patient populations of Pradaxa® users;
j. failed to provide adequate warnings regarding the increased risk of gastrointestinal bleeds in those taking Pradaxa®, especially, in those patients with a prior history of gastrointestinal issues and/or upset;
k. failed to include a “BOXED WARNING” about serious bleeding events associated with Pradaxa®;
l. failed to include a “Bolded Warning” about serious bleeding events associated with Pradaxa®; and
m. in their “Medication Guide” intended for distribution to patients to whom Pradaxa® has been prescribed, Defendants failed to disclose to patients that there is no drug, agent or means to reverse the anticoagulation effects of Pradaxa® and that if serious bleeding occurs, such irreversibility could have permanently disabling, life-threatening or fatal consequences.
End of Pradaxa Lawsuit Excerpt
Comment on Pradaxa Lawsuit Involvement
Best Legal Source was not involved in the Pradaxa Lawsuit excerpt above. You can view the Pradaxa Lawsuit in its entirety by searching through public record lawsuit search engines. The aim of Best Legal Source is to assist the victim of pharmaceutical drugs in finding a Pradaxa Lawyer to assist them with their Pradaxa Lawsuit.
Pradaxa Lawsuit Final Statement by Best Legal Source
The form at the top of our page or the number (800) 611-7080 will connect you with Best Legal Source. We will promptly assist you in receiving the contact information for a Pradaxa Lawyer who can best handle your Pradaxa Lawsuit. Time is crucial to the success of your potential Pradaxa Lawsuit. Don’t delay in calling us for answers concerning the search for a qualified Pradaxa Lawyer.
Pradaxa Lawyer Resource Page